Neurology

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Neurology, Week, Narcolepsy, Somnolence, Memory, Cataplexy, Central nervous system, Patient, CNS, Montefiore Medical Center, EDS, Concentrate, SYMPHONY, Epworth Sleepiness Scale, Quality of life, Therapy, Cognition, Concurrency, ESS, Reboxetine, Pharmaceutical industry

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.

Key Points: 
  • AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.
  • SYMPHONY was a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial in which 90 patients with a diagnosis of narcolepsy with cataplexy were randomized to treatment with AXS-12 or placebo for 5 weeks.
  • “The SYMPHONY Phase 3 trial results confirm the promise and potential of AXS-12 for the treatment of narcolepsy,” said Dr. Herriot Tabuteau, CEO of Axsome Therapeutics.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss the topline SYMPHONY study results in narcolepsy.

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Neurology, Sleep, Depression, Somnolence, Deficit spending, Thomas Jefferson University, Partnership, Central nervous system, NT1, Cataplexy, Patient, CNS, Sleep disorder, Cognitive deficit, Ageing, EDS, Columbia, Anxiety, Hallucination, Narcolepsy Network, Epworth Sleepiness Scale, Life, Therapy, Sleep paralysis, ESS, Medical director, Idiopathic hypersomnia, FDA, Human, Nursing

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline results from the CRESCENDO (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy) survey of patients with narcolepsy type 1 (NT1, i.e., narcolepsy with cataplexy) receiving treatment, demonstrating high rates of persistent symptoms and significant patient burden, despite being on current treatments. CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.

Key Points: 
  • CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.
  • All patients taking part in the survey were currently undergoing treatment for NT1.
  • The most common treatments were wake promoting agents (about 53% of surveyed patients), oxybates (47%), and stimulants (42%).
  • Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings.

C.K. McWhorter Introduces Ultra-Elite Wellness Chateau Collection: Elevating Luxury Hospitality with Holistic Well-being

Retrieved on: 
Saturday, March 23, 2024
Commitment, Health, Neurology, Elite, Ultra, Collection, Psychology, Social, Empowerment, Heart, NBA, Social change, Tourism

Rooted in innovation and dedicated to holistic well-being, this transformative project represents the epitome of refined hospitality.

Key Points: 
  • Rooted in innovation and dedicated to holistic well-being, this transformative project represents the epitome of refined hospitality.
  • Elevating Luxury Health & Wellness:
    Scheduled to commence development in 2024, the Ultra-Elite Wellness Chateau Collection promises to redefine luxury hospitality by seamlessly integrating state-of-the-art wellness facilities with opulent accommodations.
  • At the heart of the Ultra-Elite Wellness Chateau Collection lies a commitment to excellence and distinction.
  • By leveraging the power of luxury hospitality for positive social change, the Ultra-Elite Wellness Chateau Collection will leave a lasting legacy of wellness, prosperity, and philanthropy.

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

Retrieved on: 
Thursday, March 21, 2024
Neurology, Farm, BioLite, Botany, Pharmaceutical industry

The property is valued at approximately $7.6 million based on a third-party valuation.

Key Points: 
  • The property is valued at approximately $7.6 million based on a third-party valuation.
  • ABVC and its subsidiary BioLite, Inc. each own 23M AIBL shares, and we believe this agreement brings an additional value of several hundred million dollars to those assets.
  • He added, "This real estate will be used to build controlled condition farms that can grow crops related to ABVC's botanical drugs.
  • This development will be important in cost-cutting and revenue generation for AIBL's major shareholder, ABVC."

Baptist Health Foundation Announces Historic $50 Million Gift from Kenneth C. Griffin

Retrieved on: 
Tuesday, March 19, 2024
Citadel, Epilepsy, Baptist Health, Neurology, Baptist Health South Florida, Science, Alzheimer's disease, Incidence, Patient, Research, History, Neuroscience, Parkinson's disease, Baptists, DSM-IV codes, Hospital, Baptist Hospital, Physician, Health, Dementia, Medicine, Pharmaceutical industry

Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.

Key Points: 
  • Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.
  • The $50 million gift from Kenneth C. Griffin, founder and CEO of Miami-based hedge fund Citadel and founder of Griffin Catalyst, will advance neurological care in the region.
  • The new Kenneth C. Griffin Center at Miami Neuroscience Institute will also help advance research related to neuroscience and neurodegenerative disorders.
  • “This extraordinary gift is a visionary contribution to the well-being of current and future generations in South Florida and beyond,” said Bo Boulenger, president and CEO of Baptist Health.

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in

Retrieved on: 
Monday, March 18, 2024
Neurology, Headache, NDS, Patient, Contraindication, Nonsteroidal anti-inflammatory drug, Chronic pain, Migraine, Health Canada, Chemical patent, PALO, OPML, Patent, Therapy, FDA

ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3

Key Points: 
  • ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3
    The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Royal Farms Demonstrates Commitment to Community with $150,000 Donation to Johns Hopkins Children's Center

Retrieved on: 
Wednesday, March 13, 2024
Royal Farms, Health, Coin, Organization, Johns Hopkins Children's Center, Neurology, Cardiology, Partnership, Patient, Farm, Hope, Operation, Neonatology, Hospital

BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.

Key Points: 
  • BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.
  • Since 1994, Royal Farms has collected over $3 million in coins from spare change donated from customers and provided it to Johns Hopkins Children’s Center to show our dedication to supporting children's health and well-being in the community.
  • "Royal Farms is honored to support the incredible work being done at Johns Hopkins Children's Center," said Jeff Mengel, Vice President of Operations at Royal Farms.
  • "We are incredibly grateful for Royal Farms' generous donation and ongoing support," said Jennifer Phelps at Johns Hopkins Children's Center.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Wednesday, March 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”